Crinetics Pharmaceuticals Inc (CRNX) - Net Assets
Based on the latest financial reports, Crinetics Pharmaceuticals Inc (CRNX) has net assets worth $1.28 Billion USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($1.40 Billion) and total liabilities ($120.68 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check CRNX asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $1.28 Billion |
| % of Total Assets | 91.39% |
| Annual Growth Rate | N/A |
| 5-Year Change | 198.87% |
| 10-Year Change | N/A |
| Growth Volatility | 60.91 |
Crinetics Pharmaceuticals Inc - Net Assets Trend (2016–2025)
This chart illustrates how Crinetics Pharmaceuticals Inc's net assets have evolved over time, based on quarterly financial data. Also explore CRNX total asset value for the complete picture of this company's asset base.
Annual Net Assets for Crinetics Pharmaceuticals Inc (2016–2025)
The table below shows the annual net assets of Crinetics Pharmaceuticals Inc from 2016 to 2025. For live valuation and market cap data, see market value of Crinetics Pharmaceuticals Inc.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $992.08 Million | -25.11% |
| 2024-12-31 | $1.32 Billion | +145.74% |
| 2023-12-31 | $539.11 Million | +70.43% |
| 2022-12-31 | $316.33 Million | -4.70% |
| 2021-12-31 | $331.94 Million | +96.51% |
| 2020-12-31 | $168.92 Million | +44.20% |
| 2019-12-31 | $117.14 Million | -26.89% |
| 2018-12-31 | $160.22 Million | +1166.60% |
| 2017-12-31 | $-15.02 Million | -142.13% |
| 2016-12-31 | $-6.20 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Crinetics Pharmaceuticals Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 141031900000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $2.41 Billion | 242.70% |
| Other Comprehensive Income | $1.75 Million | 0.18% |
| Total Equity | $992.08 Million | 100.00% |
Crinetics Pharmaceuticals Inc Competitors by Market Cap
The table below lists competitors of Crinetics Pharmaceuticals Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Vietjet Aviation JSC
VN:VJC
|
$3.88 Billion |
|
Sphere Entertainment Co.
NYSE:SPHR
|
$3.88 Billion |
|
PT Alamtri Resources Indonesia Tbk
JK:ADRO
|
$3.88 Billion |
|
Hilton Grand Vacations Inc
NYSE:HGV
|
$3.88 Billion |
|
Canadian Apartment Properties Real Estate Investment Trust
TO:CAR-UN
|
$3.88 Billion |
|
Motor Oil (Hellas) Corinth Refineries S.A
AT:MOH
|
$3.88 Billion |
|
Skyline Corporation
NYSE:SKY
|
$3.87 Billion |
|
Comstock Resources Inc
NYSE:CRK
|
$3.87 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Crinetics Pharmaceuticals Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 1,324,805,000 to 992,083,000, a change of -332,722,000 (-25.1%).
- Net loss of 465,317,000 reduced equity.
- Other comprehensive income increased equity by 790,000.
- Other factors increased equity by 131,805,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-465.32 Million | -46.9% |
| Other Comprehensive Income | $790.00K | +0.08% |
| Other Changes | $131.81 Million | +13.29% |
| Total Change | $- | -25.11% |
Book Value vs Market Value Analysis
This analysis compares Crinetics Pharmaceuticals Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.49x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | $-0.45 | $36.78 | x |
| 2017-12-31 | $-1.08 | $36.78 | x |
| 2018-12-31 | $-3.57 | $36.78 | x |
| 2019-12-31 | $4.85 | $36.78 | x |
| 2020-12-31 | $5.55 | $36.78 | x |
| 2021-12-31 | $8.64 | $36.78 | x |
| 2022-12-31 | $6.09 | $36.78 | x |
| 2023-12-31 | $9.28 | $36.78 | x |
| 2024-12-31 | $16.40 | $36.78 | x |
| 2025-12-31 | $10.55 | $36.78 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Crinetics Pharmaceuticals Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -46.90%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -6046.22%
- • Asset Turnover: 0.01x
- • Equity Multiplier: 1.14x
- Recent ROE (-46.90%) is below the historical average (-27.74%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | 0.00% | -1021.90% | 0.05x | 0.00x | $-5.40 Million |
| 2017 | 0.00% | -447.78% | 0.13x | 0.00x | $-7.65 Million |
| 2018 | 0.00% | -1116.76% | 0.01x | 0.00x | $-22.78 Million |
| 2019 | -42.29% | -4152.14% | 0.01x | 1.11x | $-61.25 Million |
| 2020 | -43.14% | -102625.35% | 0.00x | 1.09x | $-89.76 Million |
| 2021 | -32.15% | -9899.72% | 0.00x | 1.06x | $-139.91 Million |
| 2022 | -50.57% | -3376.69% | 0.01x | 1.11x | $-191.59 Million |
| 2023 | -39.79% | -5345.85% | 0.01x | 1.18x | $-268.44 Million |
| 2024 | -22.52% | -28720.69% | 0.00x | 1.08x | $-430.89 Million |
| 2025 | -46.90% | -6046.22% | 0.01x | 1.14x | $-564.53 Million |
Industry Comparison
This section compares Crinetics Pharmaceuticals Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $190,374,900
- Average return on equity (ROE) among peers: -53.67%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Crinetics Pharmaceuticals Inc (CRNX) | $1.28 Billion | 0.00% | 0.09x | $3.88 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $91.45 Million |
| Abcellera Biologics Inc (ABCL) | $1.23 Billion | 12.85% | 0.25x | $1.60 Billion |
| Abeona Therapeutics Inc (ABEO) | $1.80 Million | -188.89% | 0.33x | $312.29 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $-18.59 Million | 0.00% | 0.00x | $174.79 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $823.18 Million |
| Arbutus Biopharma Corp (ABUS) | $101.97 Million | -62.52% | 0.34x | $854.72 Million |
| ABVC Biopharma Inc (ABVC) | $10.00K | -200.00% | 3.00x | $27.18 Million |
| Abivax SA American Depositary Shares (ABVX) | $34.66 Million | -45.66% | 0.56x | $9.73 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $540.89 Million | -31.04% | 0.29x | $3.64 Billion |
About Crinetics Pharmaceuticals Inc
Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in a Phase 3 clinical trial for the treatment of acrome… Read more